PARP1 and prostate carcinoma: Subsequently, HRD including not only BRCA but other HR repair gene deficiencies could benefit from PARP inhibitors in ovarian cancer or prostate cancer.130,134–136 Furthermore, in platinum sensitive ovarian cancer patients, olaparib, rucaparib and niraparib extended mPFS irrespective of BRCA or HR repair gene background.